RTOG: Hormone Therapy Increases Survival When Combined With Radiation Therapy
Zaltrap Shows Improvement in Survival In Stage IV Metastatic Colorectal Cancer
Trial: Decitabine Improves Survival in Myeloid Leukemia
Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival
VEGF Levels Can Predict Tumor’s Resistance to Avastin
More Patients Get Screened, Colorectal Death Rates Drop
Revlimid Shows 91 Percent Response in Non-Hodgkin’s
Revlimid Also Demonstrates Response in Mantle Cell
FPD-R Regimen Well-Tolerated, With 63 Percent Complete Response
Overall Cancer Mortality Rates Higher For Men Than Women
New Model For Risk Assessment Includes Alcohol, Exercise, Weight
Researchers Identify Five Genes Associated With Melanoma Risk
Stereotactic Body Radiotherapy Could Improve Overall Survival
CMS Issues Coverage Decision For Provenge in Prostate Cancer
Clinical Trials Approved By NCI CTEP Last Month
Approval Granted For New Formulation of Lupron Depot
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - Alec Kimmelman announced as next CEO and Dean of NYU Langone Health
